Catalyst Ortho Tops 10K Shoulder Replacements, Secures $20M Financing

Catalyst OrthoScience announced it has topped 10,000 total shoulder arthroplasty (TSA) procedures. The company also closed $20 million in equity and venture debt financing with funding partners RC Capital, Mutual Capital Partners and Bridge Bank.
 
The company said the ten thousand completed TSA procedures reaffirms surgeons’ and patients’ choices made at the forefront of shoulder arthroplasty. The milestone and investment positions Catalyst for further growth and continued innovation in the market.
 
Catalyst said the company is poised for the next stage of commercial adoption. This empowers it to expand its distribution channel, further invest in talent and training, and launch new products.
 
The company received U.S. Food and Drug Administration (FDA) 510(k) clearance for its fully convertible stemmed total shoulder arthroplasty system with an ellipsoid anatomic head last year.
 
“Catalyst has made significant progress since its first case in 2016,” said Carl O’Connell, CEO of Catalyst. “Our unique ability to blend true innovation with unmatched efficiency and predictable outcomes is transforming an industry that has long been burdened by solutions that introduce inefficiencies and inflate procedural costs without also delivering improved patient outcomes. At Catalyst, we’re closing those gaps with our single-tray systems, proprietary instrumentation, fewer surgical steps, and purposefully designed implants. This is increasingly important as procedures shift to ambulatory surgery centers (ASC) where there is a growing desirability for solutions that reduce case turnaround times and sterilization costs, limit storage space needs, and ease the workload on the surgical team.”